About
Lenvatinib is a multi-kinase inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). It also inhibits other pro-angiogenic and oncogenic signaling pathways associated with fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, platelet-derived growth factor receptor alpha (PDGFRα), KIT, and RET proto-oncogene. By targeting these pathways, lenvatinib effectively inhibits tumor growth, angiogenesis, and metastatic progression.
This targeted therapy is crucial in managing various advanced cancers where these pathways are dysregulated. Its mechanism of action involves blocking the signaling cascades essential for tumor cell proliferation and the formation of new blood vessels that supply tumors, thereby starving the tumor and inhibiting its growth. The dual inhibition of VEGF and FGF pathways provides a broad anti-angiogenic and anti-tumor effect, making it a valuable agent in oncology for specific indications.
Uses
- Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine.
- Advanced renal cell carcinoma (RCC) in combination with everolimus.
- Hepatocellular carcinoma (HCC) as a first-line treatment.
- Endometrial carcinoma in combination with pembrolizumab.
Directions For Use
Take orally once daily, with or without food, as directed by your physician. Swallow capsules whole with water.
Benefits
- Effective in treating advanced differentiated thyroid cancer.
- Improves progression-free survival in renal cell carcinoma.
- Demonstrates significant efficacy in hepatocellular carcinoma.
- Targets multiple pathways involved in cancer growth and angiogenesis.
- Offers a treatment option for cancers resistant to other therapies.
- Available in oral capsule form for convenient administration.
Side Effects
- Hypertension (high blood pressure)
- Fatigue and asthenia
- Diarrhea
- Decreased appetite
- Weight loss
- Nausea and vomiting
- Proteinuria (protein in urine)
- Palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome)
- Hypothyroidism
- Headache
- Dysphonia (hoarseness)
- Arterial thromboembolic events
Safety Measures
- Alcohol - Avoid or limit alcohol consumption as it may exacerbate liver-related side effects or interact with the medication's metabolism.
- Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
- Breastfeeding - Not recommended during breastfeeding as lenvatinib may be excreted in human milk and harm the infant.
- Liver - Use with caution in patients with severe hepatic impairment; dose adjustment may be necessary. Monitor liver function closely.
- Kidney - Use with caution in patients with severe renal impairment; dose adjustment may be necessary. Monitor renal function regularly.
- Lung - Rare cases of interstitial lung disease/pneumonitis have been reported. Monitor for new or worsening respiratory symptoms.
Disclaimer
MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.
Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.
Our goal is to complement, not replace, the essential doctor-patient relationship.
| Shipping Cost |
|
| Shop Location | Assam, India |
No comments found for this product. Be the first to comment!